Genentech, AstraZeneca, City of Hope National Medical Center infectious news

Genentech said it settled its patent litigation with AstraZeneca’s MedImmune Inc. subsidiary related to the Cabilly II patent (U.S. Patent No. 6,331,415), which covers methods of antibody production. The settlement resolves disputes over MedImmune’s Synagis palivizumab, an antibody marketed to prevent pediatric respiratory syncytial virus (RSV), and motavizumab, a humanized RSV antibody under FDA review to prevent RSV. Terms of the settlement were not disclosed. MedImmune pays Genentech royalties on sales of Synagis. ...